What is Genetesis?
Genetesis is a pioneering healthcare technology firm dedicated to transforming the standard of care for patients presenting with chest pain. At the core of its innovation is the CardioFlux system, a sophisticated diagnostic tool that utilizes magnetocardiography to detect functionally significant ischemia with unprecedented speed and precision. By providing a non-invasive alternative to traditional cardiac testing, Genetesis addresses a critical gap in hospital workflows, effectively reducing patient wait times and improving diagnostic accuracy.
The company's market position is defined by its commitment to clinical efficiency and patient-centric outcomes. By integrating its technology into existing hospital infrastructure, Genetesis not only enhances the diagnostic capabilities of healthcare professionals but also optimizes the overall economic efficiency of cardiac care delivery. As the firm continues to refine its CardioFlux Membership program, it remains at the forefront of the digital health revolution, bridging the gap between complex medical diagnostics and actionable clinical insights.
How much funding has Genetesis raised?
Genetesis has raised a total of $35.9M across 5 funding rounds:
Angel/Seed
$1.2M
Series A
$7.5M
Series B
$9.2M
Debt
$508K
Series C
$17.5M
Angel/Seed (2016): $1.2M with participation from CincyTech and LOUD Capital
Series A (2018): $7.5M, investors not publicly disclosed
Series B (2020): $9.2M supported by TDK Ventures
Debt (2021): $508K featuring PPP
Series C (2022): $17.5M backed by Mithril Capital Management, CincyTech, Ohio Innovation Fund, JobsOhio, and Cercano Management
Key Investors in Genetesis
Mithril Capital Management
A long-term venture capital firm co-founded by Peter Thiel that focuses on investing in transformative technologies across various sectors to build enduring businesses.
CincyTech
A public-private seed-stage investor based in Ohio, specializing in high-growth sectors including life sciences, digital health, and enterprise software.
Ohio Innovation Fund
A venture firm dedicated to supporting disruptive startups in medtech, AI, and biotech by providing strategic guidance and access to a deep network of industry experts.
What's next for Genetesis?
With the successful closure of its latest financing round, Genetesis is poised to enter a phase of aggressive commercial expansion and technological refinement. The strategic allocation of this capital will likely focus on scaling the deployment of the CardioFlux platform across major healthcare systems, thereby solidifying its footprint in the preventive cardiology market. Furthermore, the company is expected to leverage its strong investor network to drive further research and development, potentially expanding its diagnostic capabilities to address a broader spectrum of cardiovascular conditions.
As the organization transitions into this next stage of maturity, the focus will shift toward long-term sustainability and the establishment of new clinical benchmarks. By maintaining its emphasis on operational excellence and data-driven innovation, Genetesis is well-equipped to navigate the complexities of the healthcare landscape, ultimately aiming to set a new global standard for cardiac imaging and patient management.
